Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: RNA-binding protein IMP3 is a novel regulator of MEK1/ERK signaling pathway in the progression of colorectal Cancer through the stabilization of MEKK1 mRNA

Fig. 1

IMP3 is upregulated in human CRC patients and predicted poor prognosis. (A) Heatmap of differentially expressed mRNAs related to RNA binding proteins between adjacent normal mucosa (N), cancer tissue (T), and liver metastases tissue (M) from 8 paired colon cancer tissues. (B) IMP3 mRNA expression level in adjacent normal mucosa (N), cancer tissue (T), and liver metastases tissue (M) from 8 paired colon cancer tissues. (C) Expression of IMP3 in the TCGA CRC RNAseq dataset (Normal n = 51, Tumor n = 647). (D) Expression of IMP3 in the FUSCC dataset (Normal n = 61, Tumor n = 72). (E) IMP3 expression in 59 paired CRC tissues and its adjacent normal mucosa. (F-H) The expression of IMP3 in CRC tissue microarrays by IHC. (F) IMP3 was overexpressed in CRC tissues (p < 0.05). (G) IMP3 overexpression was associated with AJCC stage (p < 0.05). (H) MP3 overexpression was associated with tumor distal metastasis (p < 0.05). (I) Representative images of IMP3 expression in CRC tissues by Western blot analysis. (J) High IMP3 expression predicted shorter DFS than that of patients with low IMP3 expression. (K) High IMP3 expression predicted shorter OS than that of patients with low IMP3 expression

Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us